We are live on
!
Find out more
O
OrbiMed Portfolio holdings
AUM
$5.05B
1-Year Est. Return
125.28%
This Fund
S&P 500
This Quarter
Est. Return
+33.86%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$6.46B
AUM Growth
+$1.05B
(+19%)
Cap. Flow
-$233M
Cap. Flow
% of AUM
-3.6%
Top 10 Holdings %
Top 10 Hldgs %
39.98%
Holding
155
New
25
Increased
25
Reduced
25
Closed
31
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alector
ALEC
|
+$249M |
| 2 |
Neurocrine Biosciences
NBIX
|
+$112M |
| 3 |
Teva Pharmaceuticals
TEVA
|
+$71.9M |
| 4 |
ENDP
Endo International plc
ENDP
|
+$58M |
| 5 |
AVDR
Avedro, Inc Common Stock
AVDR
|
+$53M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$259M |
| 2 |
Biogen
BIIB
|
+$235M |
| 3 |
AGN
Allergan plc
AGN
|
+$128M |
| 4 |
CVS Health
CVS
|
+$52M |
| 5 |
Centene
CNC
|
+$48.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 95.53% |
| 2 | Financials | 1.14% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Ascendis Pharma A/S
ASND
$16.7B
| $467M | 7.23% |
3,970,673
-116,700
| -3% | -$10.2M |
|
|
TCDA
2
DELISTED
Tricida, Inc. Common Stock
TCDA
| $421M | 6.51% |
10,889,280
| – | – |
|
|
CMTA
3
DELISTED
Clementia Pharmaceuticals Inc.
CMTA
| $272M | 4.21% |
10,425,225
| – | – |
|
|
ALXN
4
DELISTED
Alexion Pharmaceuticals
ALXN
| $265M | 4.1% |
1,957,200
-90,200
| -4% | -$11.2M |
|
|
5
Alector
ALEC
$169M
| $247M | 3.82% |
+13,182,329
| New | +$249M |
|
6
Boston Scientific
BSX
$68.5B
| $222M | 3.44% |
5,790,400
| – | – |
|
7
Merck
MRK
$326B
| $214M | 3.31% |
2,693,465
+78,705
| +3% | +$5.89M |
|
8
Vertex Pharmaceuticals
VRTX
$124B
| $176M | 2.72% |
955,300
-177,900
| -16% | -$32.9M |
|
|
9
Neurocrine Biosciences
NBIX
$18.4B
| $162M | 2.5% |
1,833,200
+1,339,000
| +271% | +$112M |
|
10
Viatris
VTRS
$20.8B
| $138M | 2.13% |
4,861,800
+875,600
| +22% | +$25.5M |
|
11
Edwards Lifesciences
EW
$48.2B
| $137M | 2.12% |
2,145,000
+748,200
| +54% | +$42.7M |
|
|
WMGI
12
DELISTED
Wright Medical Group Inc
WMGI
| $132M | 2.04% |
4,187,799
-718,100
| -15% | -$21.8M |
|
13
Thermo Fisher Scientific
TMO
$214B
| $122M | 1.9% |
447,300
+9,800
| +2% | +$2.44M |
|
14
Intuitive Surgical
ISRG
$130B
| $120M | 1.86% |
630,900
+119,400
| +23% | +$21.2M |
|
15
Guardant Health
GH
$19B
| $118M | 1.82% |
1,534,464
| – | – |
|
|
THOR
16
DELISTED
Synthorx, Inc. Common Stock
THOR
| $108M | 1.68% |
5,316,355
| – | – |
|
17
Sarepta Therapeutics
SRPT
$1.63B
| $98.7M | 1.53% |
828,400
+47,400
| +6% | +$6.09M |
|
18
Elevance Health
ELV
$83.7B
| $93.3M | 1.44% |
325,200
+19,800
| +6% | +$5.73M |
|
19
Bausch Health
BHC
$1.69B
| $92.4M | 1.43% |
3,740,700
+140,400
| +4% | +$3.35M |
|
|
PRNB
20
DELISTED
Principia Biopharma Inc. Common Stock
PRNB
| $88.6M | 1.37% |
2,605,713
| – | – |
|
21
Regeneron Pharmaceuticals
REGN
$72.9B
| $88.2M | 1.37% |
214,800
-7,300
| -3% | -$3.01M |
|
|
DCPH
22
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $84M | 1.3% |
3,618,171
+1,175,971
| +48% | +$30.8M |
|
23
Inspire Medical Systems
INSP
$1.5B
| $83.5M | 1.29% |
1,471,000
-358,449
| -20% | -$19.4M |
|
|
IMMU
24
DELISTED
Immunomedics Inc
IMMU
| $82M | 1.27% |
4,270,403
-697,000
| -14% | -$11.2M |
|
25
eHealth
EHTH
$43.2M
| $73.6M | 1.14% |
1,181,214
+81,214
| +7% | +$4.48M |
|
Similar funds
HSA
LIM
NL
BPWM
LFG
JIM
CTC
PAMP
OrbiMed's Q1 2019 Portfolio in Review
As of Q1 2019, OrbiMed held 155 positions worth $6.46B, up 19% from $5.41B the previous quarter. Its ten largest holdings account for 40% of the portfolio.
OrbiMed withdrew a net $233M in Q1 2019, closing 31 positions and reducing 25 holdings. Its most notable exit was Allergan plc, an estimated $128M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 95% a quarter earlier, followed by Financials.
Against the trend, OrbiMed opened a new position in Alector worth $247M.
- OrbiMed's largest Q1 2019 buy was Alector: 13,182,329 shares worth $247M.
- OrbiMed added most to Neurocrine Biosciences in Q1 2019, an estimated $112M increase.
- OrbiMed's biggest Q1 2019 reduction was Celgene Corp, cutting an estimated $259M.
- OrbiMed fully exited Allergan plc in Q1 2019, selling an estimated $128M.
- OrbiMed's ten largest holdings make up 40% of its $6.46B portfolio in Q1 2019.
- OrbiMed opened 25 new positions and closed 31 in Q1 2019.
- OrbiMed's portfolio value rose 19% quarter-over-quarter to $6.46B.
Based on OrbiMed's 13F filing for Q1 2019, filed 15 May 2019.